The tirzepatide dosing protocol: what it actually does and why it starts low

The biggest myth: that a higher dose means a better result sooner

Most people who start tirzepatide assume the goal is to reach 15 mg as quickly as possible. The logic feels obvious, bigger dose, bigger effect. In practice, the licensed tirzepatide protocol works quite differently, and that assumption can lead to real discomfort.

The 2.5 mg starting dose is not a therapeutic target. Its job is adjustment. Tirzepatide slows gastric emptying and changes how your gut signals hunger and fullness, and those shifts take time for your system to settle around. Starting at 2.5 mg keeps nausea, vomiting and other gastrointestinal effects manageable during that settling-in window. Rushing past it tends to mean more side effects, not faster progress.

The same logic applies at every rung of the schedule. Holding each dose for roughly four weeks before considering an increase isn't arbitrary, it gives the prescriber time to assess how you're tolerating the current level and whether there is clinical reason to move. Some people stay at an intermediate dose long-term. That is a legitimate clinical outcome, not a failure. You can read more about how this plays out dose by dose in our detailed tirzepatide dosing breakdown.

Letting go of the 15 mg-or-bust mindset is, for most people, the thing that makes the first few months easier.

What the protocol looks like week by week, and where it can flex

The schedule in the Mounjaro Summary of Product Characteristics sets out a clear default path: 2.5 mg for the first four weeks, then an increase to 5 mg, with subsequent steps at roughly four-week intervals up to the maximum tolerated dose. Each Mounjaro KwikPen contains four weekly doses, so the titration steps align neatly with one pen per month at each level.

Where the protocol flexes is in both directions. If side effects at a new dose are significant, a prescriber can recommend staying at the current level for longer (sometimes eight weeks or more) before moving up. The protocol is a framework, not a fixed rail. Equally, if someone reaches a dose at which weight loss has plateaued and they are tolerating treatment well, their prescriber may consider moving further. The SURMOUNT-1 trial, published in the New England Journal of Medicine, found that participants taking tirzepatide 15 mg lost around 20 to 21 percent of body weight on average over 72 weeks, the headline figure most people associate with the medicine. But that result came from a structured clinical context with supervised titration, and our Mounjaro dosing guide explains how that supervised structure translates into everyday practice.

For a closer look at how these steps interact with weight-loss goals specifically, the tirzepatide dosing for weight loss page covers that in full.

Side effects along the protocol (and when they tend to ease

The gastrointestinal side effects of tirzepatide) nausea, loose stools, constipation, indigestion and occasionally vomiting, are most noticeable at two points: when treatment begins and after each dose increase. This is expected and described in the NHS tirzepatide medicines page. For most people, symptoms settle within days to a couple of weeks as the body adapts to each new level.

Eating smaller portions, avoiding rich or fatty meals immediately after injecting, and staying hydrated all help. These are practical habits, not medical instructions, your prescriber and the Patient Information Leaflet are the right sources for guidance specific to your situation.

A less common but serious side effect worth knowing: acute pancreatitis. If you develop severe stomach pain that spreads toward your back, get medical help promptly rather than waiting. The MHRA highlighted pancreatitis as a known risk with GLP-1 medicines in a Drug Safety Update issued in January 2026, and flagged that it should not be dismissed as ordinary nausea. Injection-site reactions (mild redness or tenderness where you inject) are also common and usually brief. Rotating between the abdomen, thigh and upper arm helps.

Who sets the protocol, and how that works at nume

The tirzepatide dosing protocol is not something you navigate alone. In the UK, tirzepatide is a Prescription-Only Medicine: a prescriber assesses suitability, sets the starting dose, and reviews each stage before any increase. At nume (at our GPhC-registered pharmacy) a GPhC-registered Independent Prescriber reads every consultation personally the same day. Not software. A clinician who can consider your full picture before making any recommendation.

Every repeat order at our pharmacy goes through clinical re-review before dispatch. That means dose increases are not automatic; they follow the same evidence-based assessment as the initial consultation. If you are considering transferring from another provider, our prescribers review your treatment history and current dose as part of that process.

The tirzepatide dosing guide on our site covers the practical detail of each step, and if you want to go deeper on how peptide concentrations and volumes work in practice, our page on tirzepatide peptide dosing walks through that in detail. For context on the cost of private tirzepatide treatment in the UK, the Eli Lilly price change page explains how market pricing shifted from late 2025. And if you'd like to understand the broader treatment landscape, our weight-loss treatment overview lays out the options clearly. When you're ready to take the next step, starting a free consultation is the place to begin, a prescriber will take it from there.